Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

Table 2

Treatment and outcome data.

Patient	Treatment before symptomatic BM	Treatment with symptomatic BM	Best systemic response	Best radiographic intracranial response	Neurological symptomatic response	Steroids (D) dose before, after treatment	TTP (months)	Progression site	Subsequent lines	Survival from symptomatic BM diagnosis or last follow-up
1	Crizotinib, ceritinib, carboplatin/pemetrexed	Lorlatinib	CR	CR	Complete resolution	10 mg, 0 mg	19	Stable	None	19 (alive)
2	Afatinib	Osimertinib	NA	NA	Deterioration	16 mg, NA	2.1	Brain	WBRT	2.8
3	Gefitinib	Osimertinib	NA	NA	Deterioration	12 mg, NA	2.3	NA	None	2.3
4	None	Afatinib	PR	PR	Clinical improvement	6 mg, NA	4.2	Lung, LN, liver	Osimertinib	5.9
5	None	Gefitinib	PR	PR	Clinical improvement	NA, NA	15.8	NA	None	15.8
6	None	Osimertinib	PR	PR	Complete resolution	8 mg, 0 mg	10.2	Brain	WBRT, HD osimertinib	15.1
7	None	Osimertinib	NA	PR	Complete resolution	4 mg, 0 mg	Stable (9.6 FU)	Stable	None	9.6 (alive)
8	None	Afatinib	PR	NA	Deterioration	10 mg, 10 mg	3.3	Brain, lung	None	3.3
9	None	Osimertinib	PR	PR	Clinical improvement	6 mg, 4 mg	Stable (9.5 FU)	Stable	None	9.5 (alive)

BM: brain metastases; D: dexamethasone; TTP: time to progression; CR: complete response; NA: not applicable; PR: partial response; FU: follow-up, month; LN: lymph nodes; WBRT: whole brain radiation therapy; HD: high dose.